Non-proteinogenic amino acids in lacticin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation

ACS Chemical Biology

Volumn 7, Issue 11, 2012, Pages 1791-1795

  Knerr, Patrick J ^a   Oman, Trent J ^a   Garcia De Gonzalo, Chantal V ^a   Lupoli, Tania J ^b   Walker, Suzanne ^c   Van Der Donk, Wilfred A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; GLYCOSYLTRANSFERASE; LACTICIN 481 DERIVATIVE; LANTIBIOTIC; PEPTIDOGLYCAN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; DRUG POTENCY; ENZYME INHIBITION; GLYCOSYLATION; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACILLUS SUBTILIS; BACTERIOCINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; GLYCOSYLATION; HUMANS; LACTOCOCCUS LACTIS; MOLECULAR SEQUENCE DATA; PENICILLIN-BINDING PROTEINS; PEPTIDOGLYCAN; PEPTIDOGLYCAN GLYCOSYLTRANSFERASE; PERMEABILITY; SERINE-TYPE D-ALA-D-ALA CARBOXYPEPTIDASE;

POSIBACTERIA;

EID: 84869477477     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb300372b     Document Type: Article

References (33)

1. Velásquez, J. E. and van der Donk, W. A. (2011) Genome mining for ribosomally synthesized natural products Curr. Opin. Chem. Biol. 15, 11-21
2. McIntosh, J. A., Donia, M. S., and Schmidt, E. W. (2009) Ribosomal peptide natural products: Bridging the ribosomal and nonribosomal worlds Nat. Prod. Rep. 26, 537-559
3. Knerr, P. J. and van der Donk, W. A. (2012) Discovery, biosynthesis, and engineering of lantipeptides Annu. Rev. Biochem. 81, 479-505
4. Oman, T. J. and van der Donk, W. A. (2010) Follow the leader: the use of leader peptides to guide natural product biosynthesis Nat. Chem. Biol. 6, 9-18
5. Bierbaum, G. and Sahl, H. G. (2009) Lantibiotics: mode of action, biosynthesis and bioengineering Curr. Pharm. Biotechnol. 10, 2-18
6. Cotter, P. D., Hill, C., and Ross, R. P. (2005) Bacterial lantibiotics: strategies to improve therapeutic potential Curr. Protein Pept. Sci. 6, 61-75
7. Breukink, E. and de Kruijff, B. (2006) Lipid II as a target for antibiotics Nat. Rev. Drug Discovery 5, 321-332
8. Schneider, T. and Sahl, H. G. (2010) Lipid II and other bactoprenol-bound cell wall precursors as drug targets Curr. Opin. Invest. Drugs 11, 157-164
9. Hsu, S.-T. D., Breukink, E., Tischenko, E., Lutters, M. A. G., de Kruijff, B., Kaptein, R., Bonvin, A. M. J. J., and van Nuland, N. A. J. (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics Nat. Struct. Mol. Biol. 11, 963-967
10. Hasper, H. E., Kramer, N. E., Smith, J. L., Hillman, J. D., Zachariah, C., Kuipers, O. P., de Kruijff, B., and Breukink, E. (2006) An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II Science 313, 1636-1637
11. Hasper, H. E., de Kruijff, B., and Breukink, E. (2004) Assembly and stability of nisin-lipid II pores Biochemistry 43, 11567-11575
12. Wiedemann, I., Benz, R., and Sahl, H.-G. (2004) Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study J. Bacteriol. 186, 3259-3261
13. Brötz, H., Bierbaum, G., Leopold, K., Reynolds, P. E., and Sahl, H. G. (1998) The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II Antimicrob. Agents Chemother. 42, 154-160
14. 2+ ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif Appl. Environ. Microbiol. 75, 4427-4434
15. Hsu, S.-T. D., Breukink, E., Bierbaum, G., Sahl, H.-G., de Kruijff, B., Kaptein, R., van Nuland, N. A. J., and Bonvin, A. M. J. J. (2003) NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles: Conformational changes are a key to antimicrobial activity J. Biol. Chem. 278, 13110-13117
16. Piard, J. C., Muriana, P. M., Desmazeaud, M. J., and Klaenhammer, T. R. (1992) Purification and partial characterization of lacticin 481, a lanthionine-containing bacteriocin produced by Lactococcus lactis subsp. lactis CNRZ 481 Appl. Environ. Microbiol. 58, 279-284
17. Oman, T. J., Knerr, P. J., Bindman, N. A., Velásquez, J. E., and van der Donk, W. A. (2012) An engineered lantibiotic synthetase that does not require a leader peptide on its substrate J. Am. Chem. Soc. 134, 6952-6955
18. Oman, T. J. and van der Donk, W. A. (2009) Insights into the mode of action of the two-peptide lantibiotic haloduracin ACS Chem. Biol. 4, 865-874
19. Dufour, A., Hindré, T., Haras, D., and Le Pennec, J.-P. (2007) The biology of lantibiotics from the lacticin 481 group is coming of age FEMS Microbiol. Rev. 31, 134-167
20. Islam, M. R., Nishie, M., Nagao, J.-i., Zendo, T., Keller, S., Nakayama, J., Kohda, D., Sahl, H.-G., and Sonomoto, K. (2012) Ring A of nukacin ISK-1: A lipid II-binding motif for type-A(II) lantibiotic J. Am. Chem. Soc. 134, 3687-3690
21. Levengood, M. R., Knerr, P. J., Oman, T. J., and van der Donk, W. A. (2009) In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids J. Am. Chem. Soc. 131, 12024-12025
22. Chen, L., Walker, D., Sun, B., Hu, Y., Walker, S., and Kahne, D. (2003) Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate Proc. Natl. Acad. Sci. U.S.A. 100, 5658-5663
23. Oman, T. J., Lupoli, T. J., Wang, T.-S. A., Kahne, D., Walker, S., and van der Donk, W. A. (2011) Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry J. Am. Chem. Soc. 133, 17544-17547
24. Hu, Y., Helm, J. S., Chen, L., Ye, X.-Y., and Walker, S. (2003) Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to lipid II J. Am. Chem. Soc. 125, 8736-8737
25. Wiedemann, I., Böttiger, T., Bonelli, R. R., Schneider, T., Sahl, H.-G., and Martínez, B. (2006) Lipid II-based antimicrobial activity of the lantibiotic plantaricin C Appl. Environ. Microbiol. 72, 2809-2814
26. Wiedemann, I., Böttiger, T., Bonelli, R. R., Wiese, A., Hagge, S. O., Gutsmann, T., Seydel, U., Deegan, L., Hill, C., Ross, P., and Sahl, H.-G. (2006) The mode of action of the lantibiotic lacticin 3147 - a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II Mol. Microbiol. 61, 285-296
27. Szekat, C., Jack, R. W., Skutlarek, D., Farber, H., and Bierbaum, G. (2003) Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin Appl. Environ. Microbiol. 69, 3777-3783
28. Cooper, L. E., McClerren, A. L., Chary, A., and van der Donk, W. A. (2008) Structure-activity relationship studies of the two-component lantibiotic haloduracin Chem. Biol. 15, 1035-1045
29. Islam, M. R., Shioya, K., Nagao, J., Nishie, M., Jikuya, H., Zendo, T., Nakayama, J., and Sonomoto, K. (2009) Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning Mol. Microbiol. 72, 1438-1447
30. Deegan, L. H., Suda, S., Lawton, E. M., Draper, L. A., Hugenholtz, F., Peschel, A., Hill, C., Cotter, P. D., and Ross, R. P. (2010) Manipulation of charged residues within the two-peptide lantibiotic lacticin 3147 Microb. Biotechnol. 3, 222-234
31. Patton, G. C., Paul, M., Cooper, L. E., Chatterjee, C., and van der Donk, W. A. (2008) The importance of the leader sequence for directing lanthionine formation in lacticin 481 Biochemistry 47, 7342-7351
32. Ye, X.-Y., Lo, M.-C., Brunner, L., Walker, D., Kahne, D., and Walker, S. (2001) Better substrates for bacterial transglycosylases J. Am. Chem. Soc. 123, 3155-3156
33. Gut, I. M., Blanke, S. R., and van der Donk, W. A. (2011) Mechanism of inhibition of Bacillus anthracis spore outgrowth by the lantibiotic nisin ACS Chem. Biol. 6, 744-752